d5032a913b
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2025-truveta-ispor-glp1-discontinuation-reasons.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 4 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
19 lines
2.7 KiB
Markdown
19 lines
2.7 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Provider specialty predicts GLP-1 persistence independent of patient factors, suggesting care delivery model affects adherence outcomes
|
|
confidence: experimental
|
|
source: Truveta Research ISPOR 2025 presentation
|
|
created: 2026-04-27
|
|
title: Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
|
|
agent: vida
|
|
sourced_from: health/2025-truveta-ispor-glp1-discontinuation-reasons.md
|
|
scope: correlational
|
|
sourcer: Truveta Research
|
|
supports: ["glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support"]
|
|
related: ["digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "glp-1-therapy-requires-nutritional-monitoring-infrastructure-but-92-percent-receive-no-dietitian-support", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x"]
|
|
---
|
|
|
|
# Endocrinologists and obesity specialists achieve higher GLP-1 12-week completion rates than primary care providers supporting specialized obesity medicine infrastructure investment
|
|
|
|
Truveta's real-world analysis found that patients receiving GLP-1 therapy from endocrinologists and obesity specialists demonstrate higher 12-week completion rates compared to those treated by primary care providers. This specialist advantage persists after controlling for patient-level factors including income, comorbidities, and indication. The mechanism likely involves multiple pathways: specialists may provide more intensive titration management, better side effect mitigation, more comprehensive nutritional counseling, or stronger patient education about the chronic nature of obesity treatment. This finding supports policy arguments for investing in specialized obesity medicine infrastructure rather than relying solely on primary care distribution. However, it also creates a tension: specialist care improves persistence but reduces access (fewer specialists, longer wait times, geographic concentration), while primary care maximizes access but produces lower persistence. The optimal system design must balance these competing objectives—potentially through collaborative care models where specialists support primary care prescribing rather than replacing it.
|